Ginkgo Bioworks (DNA) vs 4D Molecular Therapeutics (FDMT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
4D Molecular Therapeutics (FDMT) has outperformed Ginkgo Bioworks (DNA) over the past year, gaining 51.3% versus a loss of 22.6%. Over five years, FDMT leads with a -53.9% price change compared with -97.6% for DNA. Ginkgo Bioworks is the larger company by market cap ($772.4 million vs $695.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DNA | FDMT |
|---|---|---|
| Share price | $11.47 | $12.59 |
| Market cap | $772.39M | $695.52M |
| 1-day change | -7.57% | +0.24% |
| YTD return | +38.03% | +67.87% |
| 1-year return | -22.60% | +51.32% |
| 5-year return | -97.59% | -53.92% |
| EPS (TTM) | $-5.06 | $-2.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $18.22 | $16.93 |
| 52-week low | $5.37 | $6.96 |
| Distance from 52-week high | -37.05% | -25.63% |
| Average volume | 1.68M | 924.05K |
| Shares outstanding | 55.38M | 55.24M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FDMT has outperformed DNA by 73.9 percentage points over the past year.
DNA vs FDMT FAQ
Which is bigger, Ginkgo Bioworks or 4D Molecular Therapeutics?
Ginkgo Bioworks (DNA) is larger, with a market capitalization of $772.39M compared with $695.52M for 4D Molecular Therapeutics (FDMT).
Which stock has performed better over the past year, DNA or FDMT?
FDMT returned +51.32% over the past 12 months, compared with -22.60% for DNA (price return, excluding dividends). Past performance does not predict future results.
Are Ginkgo Bioworks and 4D Molecular Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.